

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

PROPOSED APPOINTMENT OF NEW EXECUTIVE DIRECTOR

PROPOSED APPOINTMENT OF NEW EXECUTIVE DIRECTOR AND MEMBER OF THE STRATEGY COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”) of RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司(the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, at a meeting of the Board held on March 14, 2025, Mr. Wen Qingkai (“**Mr. Wen**”) has been nominated as a candidate for appointment as an executive Director of the Company, which shall be subject to the consideration and approval at the extraordinary general meeting of the Company (the “**EGM**”) to be held on Wednesday, April 2, 2025. If the proposed appointment has been approved, the term of office of Mr. Wen will be effective from the date of the EGM until the expiry of the term of the second session of the Board. At the expiry of such term of office, the term is renewable upon re-election.

The Board further announces that Mr. Wen has also been nominated as a member of the strategy committee of the Board, subject to the approval of his appointment as an executive Director at the EGM until the expiry of the term of the second session of the Board.

The biographical details of Mr. Wen are set out below:

Mr. Wen Qingkai, aged 58, was appointed as the board secretary of the Company on May 11, 2020 and is primarily responsible for overseeing financing activities, internal control and securities and listing matters of the Group. Mr. Wen has more than 20 years of experience in capital operation and corporate governance. He has been serving as a supervisor of Heyuan Aidisi Biomedical Technology Co., Ltd. (煙台市和元艾迪斯生物醫藥科技有限公司), an investee of the Company, since September 2018, and is responsible for supervising its board, business and operational matters. From February 2004 to May 2019, he served as the vice president in Yantai Rongchang Pharmaceutical Co., Ltd. (煙台榮昌製藥股份有限公司) (“**RC Pharma**”), the sole shareholder of the predecessor of the Company prior to the reorganization, and was responsible for its corporate management, internal control and information technology matters. He has also been serving as a director of RC Pharma since May 2016. From March 2010 to June 2020, he served as a director of Rongchang Pharma (Zibo) Co., Ltd., a subsidiary of RC Pharma. He has been appointed as a director at Yantai MabPlex International Biomedical Co., Ltd. since October 2015. Mr. Wen obtained his bachelor’s degree in physics at Yangzhou University in the PRC in June 1990 and master’s degree in philosophy of science and technology at Zhejiang University in the PRC in May 1995.

Subject to the approval by the shareholders of the Company of his appointment, the Company will enter into a service contract with Mr. Wen and his term of office shall be effective from the date of the consideration and approval at the EGM and end on the expiry of the term of the second session of the Board. At the expiry of such term of office, the term is renewable upon re-election. Pursuant to the service contract, Mr. Wen will not receive any director's fee for serving as an executive Director and Board committee member(s) but will receive remuneration based on his specific positions with the Company.

As at the date of this announcement, the interests of Mr. Wen in the shares of the Company (the “**Shares**”), underlying Shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”) are set out below:

	Nature of interest	Number of Shares or underlying Shares	Approximate percentage in relevant class of Shares ⁽¹⁾	Approximate percentage of shareholding ⁽¹⁾
Mr. Wen ⁽²⁾⁽³⁾	Interests held jointly with another person	193,371,805 A Shares	54.51%	35.52%
	Other	118,150 A Shares	0.03%	0.02%
	Interests held jointly with another person	24,879,041 H Shares	13.12%	4.57%

Notes:

- (1) The calculation is based on percentage of shareholding in a total of 544,332,083 Shares, which consists of 189,581,239 H Shares and 354,750,844 A Shares as of the date of this announcement.
- (2) As at the date of this announcement, each of Yantai Rongda Venture Capital Center (Limited Partnership) (煙台榮達創業投資中心(有限合夥)) (“**Rongda**”), Yantai Rongqian Enterprise Management Center (Limited Partnership) (煙台榮謙企業管理中心(有限合夥)) (“**Rongqian**”), Yantai Rongshi Enterprise Management Center (Limited Partnership) (煙台榮實企業管理中心(有限合夥)) (“**Rongshi**”), Yantai Rongyi Enterprise Management Center (Limited Partnership) (煙台榮益企業管理中心(有限合夥)) (“**Rongyi**”), Yantai Rongjian Enterprise Management Center (Limited Partnership) (煙台榮建企業管理中心(有限合夥)) (“**Rongjian**”) was a limited partnership established in the PRC. Each of Rongda, Rongqian, Rongshi, Rongyi and Rongjian is an employee incentive platform and held 102,381,891, 18,507,388, 9,190,203, 16,630,337 and 2,163,655 A Shares in the Company, respectively. Mr. Wang Weidong, an executive Director and the chairman of the Board, is the executive partner of each of Rongda, Rongqian, Rongshi, Rongyi and Rongjian. As such, under the SFO, Mr. Wang Weidong is deemed to be interested in the equity interests held by Rongda, Rongqian, Rongshi, Rongyi and Rongjian.

Further, as at the date of this announcement, RongChang Holding Group LTD. was a company incorporated in the British Virgin Islands. Mr. Wang Weidong was the sole director of RongChang Holding Group LTD. and RongChang Holding Group LTD. is accustomed to act in accordance with Mr. Wang Weidong's instructions. As such, under the SFO, Mr. Wang Weidong is deemed to be interested in the equity interests held by RongChang Holding Group LTD.

As at the date of this announcement, I-NOVA Limited was a company incorporated in the British Virgin Islands and was wholly-owned by Dr. Fang Jianmin, an executive Director. As such, under the SFO, Dr. Fang Jianmin is deemed to be interested in the equity interests held by I-NOVA Limited.

On April 16, 2020, Mr. Wang Weidong (an executive Director and the chairman of the Board), Dr. Fang Jianmin (an executive Director), Mr. Lin Jian (an executive Director), Dr. Wang Liqiang (a non-executive Director), Mr. Wang Xudong, Mr. Deng Yong, Mr. Xiong Xiaobin, Mr. Wen, Ms. Yang Minhua, Mr. Wei Jianliang, Rongda, RongChang Holding LTD. and I-NOVA Limited (each being a controlling shareholder of the Company, and collectively referred to as the “**Concert Parties**”) entered into a concert party agreement to confirm that they have acted in concert in the management, decision-making and all major decisions of the Group. As such, each of the Concert Parties is deemed to be interested in the Shares each other is interested in.

- (3) As of the date of this announcement, Mr. Wen was granted restricted Shares under the 2022 Restricted A Share Incentive Scheme of the Company adopted by the Company on December 28, 2022 and the 2023 Restricted A Share Incentive Scheme of the Company adopted by the Company on December 28, 2023 with attribution conditions attached thereto. As such, under the SFO, Mr. Wen is deemed to be interested in the equity interests underlying the aforesaid restricted Shares.

Save as disclosed above, as at the date of this announcement, Mr. Wen has confirmed that (i) he does not hold any other position with the Company or other members of the Group; (ii) he does not hold, and has not held in the last three years, any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) he has no relationship with any Director, supervisor, senior management, substantial or controlling shareholder of the Company; and (iv) he does not have any interest in the Shares, underlying Shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Wen has confirmed that (i) there is no other information in relation to his appointment which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; and (ii) there is no other matter in relation to his appointment that needs to be brought to the attention of the shareholders of the Company.

EGM

The EGM of the Company will be held on Wednesday, April 2, 2025 for the purpose of considering the resolution in relation to the appointment of Mr. Wen as an executive Director. The Company will make available a circular containing, among others, details of the proposed appointment of Mr. Wen as new executive Director, together with the notice of the EGM, to the shareholders of the Company in due course.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, The People’s Republic of China
March 14, 2025

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* *For identification purpose only*